HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E4005 Decamethylcyclopentasiloxane Decamethylcyclopentasiloxane(Cyclomethicone 5) is an organosilicon compound. It is used in cosmetic and personal products as a skin emollient. Aug 16 2023
E4007 L-Sulforaphane L-Sulforaphane ((R)-Sulforaphane) is a highly potent inducer of the Keap1/Nrf2/ARE pathway. It is a more potent inducer of the carcinogen-detoxifying enzyme systems in rat liver and lung than the S-isomer. Aug 15 2023
E2984 GSK-7975A GSK-7975A is a potent and orally available inhibitor of CRAC channel. It reduces FcεRI-dependent Ca2+ influx and reduces the release of histamine, leukotriene C4, and cytokines (IL-5/-8/-13 and TNFα). Aug 15 2023
E4001 Sodium pyrophosphate decahydrate Sodium pyrophosphate decahydrate acts as a buffering agent, a chelator and a hydrated salt nucleating agent. Sodium pyrophosphate decahydrate can also be used to a raw material for synthetic laundry scent additives. Aug 15 2023
E1410 Fluspirilene Fluspirilene(R 6218; Redeptin) is a non-competitive antagonist of L-type calcium channels with an IC50 of 0.03 μM in cell-free assays. Fluspirileneis a long-acting injectable depot antipsychotic agent used for schizophrenia. Aug 13 2023
E1468 MSU-42011 MSU-42011 is an orally active agonist of retinoid X receptor (RXR). MSU-42011 inhibits the expression of iNOS and p-ERK protein. It exhibits immunomodulatory and antitumor activity. MSU-42011 can be used for cancer research. Aug 13 2023
A2370 Elezanumab (Anti-RGMA) Elezanumab (Anti-RGMA) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway with IC50 of 97 pM. MW: 146.44 kD. Aug 10 2023
A2371 Anti-PVRIG Anti-PVRIG is a humanized, hybridoma monoclonal antibody against the poliovirus receptor-related immunoglobulin (PVRIG; PVR Related Immunoglobulin Domain Containing Protein; CD112R), with potential immune checkpoint inhibitory and antineoplastic activities.MW: 145.5 kD. Aug 10 2023
A2372 Apamistamab (Anti-PTPRC / CD45) Apamistamab (Anti-PTPRC / CD45) is an IgG1 anti-CD45 monoclonal antibody (MoAb). Note: This antibody is not labeled with the radioisotope iodine (-131). MW: 145.5 kD. Aug 10 2023
A2373 Neihulizumab (Anti-PSGL1 / CD162) Neihulizumab (Anti-PSGL1 / CD162) is a humanized, agonistic monoclonal antibody against P selectin glycoprotein ligand-1 (PSGL-1, SELPLG, CD162) with potential immunosuppressive activity. It can halt the progression of T-cell-mediated autoimmune diseases and acute graft-versus-host disease (GvHD). MW: 150 kD. Aug 10 2023
A2374 Crizanlizumab (Anti-P-Selectin / CD62p) Crizanlizumab (Anti-P-Selectin / CD62p) is a humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. MW: 144.24 kD. Aug 10 2023
A2375 Rolinsatamab (Anti-PRLR / Prolactin Receptor) Rolinsatamab (Anti-PRLR / Prolactin Receptor) is a fully humanized bispecific monoclonal antibody that targets IL-4 and IL-13. MW: 145.5 kD. Aug 10 2023
A2376 Anti-Phosphorylcholine Anti-Phosphorylcholine is a antibody targeting phosphorylcholine (PC).They are known to contribute to the immune defense against a variety of microbial infections. MW: 145.5 kD. Aug 10 2023
A2377 Bavituximab (Anti-Phosphatidylserine) Bavituximab (Anti-Phosphatidylserine) is a chimeric, IgG1 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. MW: 145.5 kD. Aug 10 2023
A2378 Rinucumab (Anti-PDGFRB / CD140b) Rinucumab (Anti-PDGFRB / CD140b) is an anti-platelet-derived growth factor receptor beta (anti-PDGFR-beta) monoclonal antibody and has a potential to study neovascular age-related macular degeneration. MW: 145.5 kD. Aug 10 2023
A2379 Olaratumab (Anti-PDGFRA / CD140a) Olaratumab (IMC-3G3; LY3012207) is a fully human IgG1 monoclonal antibody directed against the platelet-derived growth factor receptor alpha (PDGFR alpha) with potential antineoplastic activity. MW: 145.5 kD. Aug 10 2023
A2381 Serplulimab (Anti-PDCD1 / PD-1 / CD279) Serplulimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.5 kD. Aug 10 2023
A2384 Anti-PAR2 Anti-PAR2 is a antibody against Protease-Activated Receptor 2 (PAR2). MW: 145.5 kD. Aug 10 2023
A2385 Zelminemab (Anti-PAC1) Zelminemab (AMG-301) is a human monoclonal antibody that inhibits the PACAP type I (PAC1) receptor. MW: 145.5 kD. Aug 10 2023
A2386 Orticumab (Anti-oxLDL) Orticumab (MLDL1278A) is an antibody targeting oxidized or malondialdehyde-modified lipoprotein (LDL) that specifically inhibits oxidised low-density lipoproteins (oxLDL). Orticumab is involved in the modulation of autoimmune responses against oxLDL and improves atherosclerosis in an animal model. MW: 145.5 kD. Aug 10 2023